<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AP</div>
ACUR -- USA Stock  

USD 0.25  0.03  13.64%

It seems ACURA PHARMACEUTICALS will continue to recover much faster as its share price surged up 15.38% today. ACURA PHARMACEUTICALS INC's current daily volatility is 10.82 percent, with a beta of 0.23 and an alpha of 0.73 over DOW. As many investors are getting excited about pharmaceutical products, it is fair to sum up ACURA PHARMACEUTICALS INC. What exactly are ACURA PHARMACEUTICALS shareholders getting in January?
Published over a month ago
View all stories for ACURA PHARMACEUTICALS | View All Stories
What does a latest ACURA PHARMACEUTICALS volatility fall mean for retail investors?
ACURA PHARMACEUTICALS INC currently holds roughly 493 K in cash with (117 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. We provide trade advice to complement the prevailing expert consensus on ACURA PHARMACEUTICALS INC. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available today.
Investing in ACURA PHARMACEUTICALS, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding ACURA PHARMACEUTICALS along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of ACURA PHARMACEUTICALS's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of ACURA PHARMACEUTICALS in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as ACURA PHARMACEUTICALS. Your research has to be compared to or analyzed against ACURA PHARMACEUTICALS's peers to derive any actionable benefits. When done correctly, ACURA PHARMACEUTICALS's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in ACURA PHARMACEUTICALS INC.

Watch out for price decline

Please consider monitoring ACURA PHARMACEUTICALS on a daily basis if you are holding a position in it. ACURA PHARMACEUTICALS is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as ACURA PHARMACEUTICALS stock to be traded above the $1 level to remain listed. If ACURA PHARMACEUTICALS stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is ACURA PHARMACEUTICALS's Liquidity

ACURA PHARMACEUTICALS financial leverage refers to using borrowed capital as a funding source to finance ACURA PHARMACEUTICALS INC ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. ACURA PHARMACEUTICALS financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between ACURA PHARMACEUTICALS's total debt and its cash.

How ACURA utilizes its cash?

To perform a cash flow analysis of ACURA PHARMACEUTICALS, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash ACURA PHARMACEUTICALS is receiving and how much cash it distributes out in a given period. The ACURA PHARMACEUTICALS cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. ACURA PHARMACEUTICALS Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. ACURA PHARMACEUTICALS reported last year Net Cash Flow from Operations of (556,200)

ACURA PHARMACEUTICALS Correlation with Peers

Investors in ACURA can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in ACURA PHARMACEUTICALS INC. Diversification will allow for the same portfolio return with reduced risk. The correlation table of ACURA PHARMACEUTICALS and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities ACURA is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of ACURA for more details

Breaking down ACURA PHARMACEUTICALS Indicators

ACURA PHARMACEUTICALS appears to be abnormally volatile, given 1 month investment horizon. ACURA PHARMACEUTICALS INC secures Sharpe Ratio (or Efficiency) of 0.043, which signifies that the company had 0.043% of return per unit of volatility over the last month. Our viewpoint regarding foreseeing the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for ACURA PHARMACEUTICALS INC, which you can use to evaluate future volatility of the entity. Please makes use of ACURA PHARMACEUTICALS INC Mean Deviation of 7.33, coefficient of variation of 1374.87, and Market Risk Adjusted Performance of 3.29 to double-check if our risk estimates are consistent with your expectations.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Will ACURA PHARMACEUTICALS latest spike continue?

The treynor ratio is down to 3.28 as of today. ACURA PHARMACEUTICALS INC is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about ACURA PHARMACEUTICALS implied risk. ACURA PHARMACEUTICALS INC is a potential penny stock. Although ACURA PHARMACEUTICALS may be in fact a good instrument to invest, many penny otc stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in ACURA PHARMACEUTICALS INC. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Takeaway on ACURA PHARMACEUTICALS Investment

While many other companies under the drug manufacturers?specialty & generic industry are still a bit expensive, ACURA PHARMACEUTICALS may offer a potential longer-term growth to retail investors. To conclude, as of the 4th of December 2020, our research shows that ACURA PHARMACEUTICALS is a rather abnormally volatile investment opportunity with a very high probability of financial unrest in the next two years. From a slightly different view, the entity currently appears to be undervalued. Our primary 30 days 'Buy-vs-Sell' recommendation on the enterprise is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of ACURA PHARMACEUTICALS INC. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to